SCHEMBL2065181

SCHEMBL2065181

N[C@H](CN1CCCCC1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 1/20 0.55
ANPEP P15144 1/20 0.52
ERAP2 Q6P179 1/20 0.52
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 3/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 1/20 0.42
CYP1A2 P05177 2/20 0.41
GRIK1 P39086 2/20 0.41
GSR P00390 2/20 0.41
GRM8 O00222 1/20 0.41
GRM6 O15303 1/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRM5 P41594 1/20 0.41
GRIA1 P42261 1/20 0.41
GRIA2 P42262 1/20 0.41
GRIA3 P42263 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL384886 1.00 DPP7 (0.55) DPP7ANPEPERAP2KMT2AMEN1
SCHEMBL1176730 1.00 DPP7 (0.55) DPP7ANPEPERAP2KMT2AMEN1
Hydrochloric Acid SCHEMBL31323997 0.98 DPP7 (0.53) DPP7ANPEPERAP2KMT2AMEN1
SCHEMBL25661087 0.98 DPP7 (0.52) DPP7ANPEPERAP2KMT2AMEN1
SCHEMBL5322593 0.98 DPP7 (0.52) DPP7ANPEPERAP2KMT2AMEN1
SCHEMBL4637391 0.83 ANPEP (0.52) DPP7ANPEPERAP2KMT2AMEN1
SCHEMBL15049655 0.81 ALDH1A1 (0.61) DPP7ANPEPKMT2AMEN1MAPT
SCHEMBL1527303 0.81 DPP7 (0.53) DPP7ANPEPERAP2KMT2AL3MBTL1
SCHEMBL1527306 0.81 DPP7 (0.53) DPP7ANPEPERAP2KMT2AL3MBTL1
SCHEMBL5533637 0.81 ALDH1A1 (0.61) DPP7ANPEPKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050119190-A1 Inhibitors of the blood-clotting factor xa, production thereof and use of the same CURACYTE AG (DE) 2005-06-02 US claimed
US-8148430-B2 Process for the hydrogenation of aromatic compounds EVONIK DEGUSSA GMBH (DE) 2012-04-03 US disclosed
US-20050119190-A1 Inhibitors of the blood-clotting factor xa, production thereof and use of the same CURACYTE AG (DE) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119190-A1 Inhibitors of the blood-clotting factor xa, production thereof and use of the same SERPINC1, TFPI, F11 DPP7 349/4885ANPEP 151/4885ERAP2 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.